According to a new release, the non-Hodgkin’s lymphoma drug market should increase from approximately $4 billion in 2009 to $8.4 billion in 2019.
The research, conducted by Decision Resources, found that in large part as a result of the launches of premium-priced therapies, the non-Hodgkin’s lymphoma market will more than double over the course of the next decade. Further, the same research noted that the market growth will be impacted by the entry of biosimilar versions of rituximab in 2013 in Europe and 2015 in the United States.
“Despite the entrance of biosimilars, rituximab will maintain its dominance as the market-leading agent through 2019,” said Decision Resources Director Andrew Merron, Ph.D. “In an attempt to reduce the negative impact of biosimilar erosion on branded rituximab, Roche has developed a novel anti-CD20 antibody—GA-101—and a subcutaneous formulation of rituximab that should help soften the anticipated drop in sales of branded, intravenously delivered rituximab.”
While there isn’t much commercial opportunity left for rituximab in non-Hodgkin’s lymphoma in terms of long-term growth, that won’t hurt the increase of its sales through 2014.
It was also noted that Celgene’s Revlimid and two novel kinase inhibitors, Pharmacyclics’ PCI-32765 and Calistoga Pharmaceuticals’ CAL-101, are raising a stir as potential game changers in the non-Hodgkins lymphoma drug market and may ultimately lead to even more sales in the arena.
These findings appeared in the Pharmacor topic called Non-Hodgkin’s Lymphoma.
